Skip to content
DataLookout
Menu

NCT07923305

Phase 2 and 3 Placebo Controlled & Long-term Extension Study of Rilzabrutinib in Adults With iCVID to Evaluate Efficacy, Safety, and Tolerability

StatusNot Yet Recruiting
PhasePhase 2/3
SponsorSanofi
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 1 with changes below, 1 re-verified with no change.

  1. Study First Submitted

Endpoints

Primary

Proportion of participants with iCVID who meet any responder definitions
Timeframe: At Week 32

Secondary (6)

Change from baseline in FACIT-Fatigue total score at Week 24 in Part A and Week 32 in Part B
Percent change from baseline in FVC% predicted at Week 32
Percent change from baseline in diffusing capacity of the lung for carbon monoxide at Week 32
Change from baseline in FACIT-dyspnea severity score at Week 24 in Part A and Week 32 in Part B
Change from baseline in time spend in moderate to vigorous physical activity measured with a wearable device
Show 1 moreShow less
Incidence of treatment-emergent adverse events (TEAE), serious AEs (SAE), TEAE leading to permanent discontinuation, adverse events of special interest (AESI)

Arms and interventions

rilzabrutinibExperimental

rilzabrutinib

placeboPlacebo comparator

placebo

Drugs: rilzabrutinib, placebo